Payment overview · 2025
General Payments
$329.64
14 reported records · 8 companies
Healthcare provider profile · identity verified
David M Olson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HARTVILLE, OH · NPI 1871828863
Verified facts
What the public records show
CMS Open Payments records show David M Olson, D.O. received $329.64 in general payments during 2025 across 14 reported records.
Dexcom, Inc. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $105.77 | 32.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $69.28 | 21.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.19 | 10.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $31.41 | 9.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.63 | 9.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.53 | 6.8% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $18.11 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.72 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.64 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $105.77 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $105.77 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $69.28 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $31.41 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 187 |
| Lisinopril | Lisinopril | 418 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 92 |
| Losartan Potassium | Losartan Potassium | 282 | 78 |
| Simvastatin | Simvastatin | 231 | 71 |
| Omeprazole | Omeprazole | 229 | 67 |
| Metformin Hcl | Metformin Hcl | 188 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 56 |
| Furosemide | Furosemide | 153 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 46 |
| Gabapentin | Gabapentin | 135 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 35 |
| Sertraline Hcl | Sertraline Hcl | 110 | 32 |
| Eliquis | Apixaban | 107 | 31 |
| Carvedilol | Carvedilol | 93 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 32 |
| Trazodone Hcl | Trazodone Hcl | 90 | 38 |
| Glipizide Er | Glipizide | 82 | 28 |
| Meloxicam | Meloxicam | 81 | 32 |
| Montelukast Sodium | Montelukast Sodium | 79 | 27 |
| Alendronate Sodium | Alendronate Sodium | 77 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 27 |
| Prednisone | Prednisone | 74 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 28 |
| Valsartan | Valsartan | 69 | 23 |
| Xarelto | Rivaroxaban | 64 | 14 |
| Warfarin Sodium | Warfarin Sodium | 59 | 14 |
| Metformin Hcl Er | Metformin Hcl | 56 | 21 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Allopurinol | Allopurinol | 55 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 16 |
| Spironolactone | Spironolactone | 47 | 17 |
| Finasteride | Finasteride | 46 | 15 |
| Jardiance | Empagliflozin | 46 | 18 |
| Potassium Chloride | Potassium Chloride | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 18 |
| Synthroid | Levothyroxine Sodium | 42 | 15 |
| Irbesartan | Irbesartan | 41 | 16 |
| Atenolol | Atenolol | 40 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 15 |
| Cephalexin | Cephalexin | 37 | 28 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 29 |
| Ozempic | Semaglutide | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Naproxen | Naproxen | 28 | 15 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 16 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 20 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.64 · 14 records | Dexcom, Inc. | AREXVY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, MOUNJARO, REPATHA, SHINGRIX, Veozah, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error